EVALUATING THE ASSOCIATION BETWEEN AGE AND FREQUENCY OF COMMON FINDINGS OF ENDOMETRIAL BIOPSIES

F ZULFIQAR; N RAHAT; H SHAHZAD; Z MOMIN; A JALBANI; P BASHIR

doi:10.54112/bcsrj.v2023i1.360

Authors

F ZULFIQAR Department of Pathology, National Institute of Child Health Karachi, Pakistan
N RAHAT DepartDepartment of Pathology, BASIC Medical Sciences Institute Jinnah Postgraduate Medical Center Karachi, Pakistan
H SHAHZAD DepartDepartment of Pathology, BASIC Medical Sciences Institute Jinnah Postgraduate Medical Center Karachi, Pakistan
Z MOMIN Surveillance Officer, Sindh blood transfusion authority Karachi, Pakistan
A JALBANI Department of Pathology, Bolan Medical Complex Hospital Quetta, Pakistan
P BASHIR Taluka hospital shahdadkot Sindh, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.360

Keywords:

Endometroid adenocarcinoma, Hyperplasia, Pre menopause, Postmenopause.

Abstract

The current analyses aimed to assess the association between age and frequency with the common findings of endometrial biopsies. The retrospective study was conducted in the Department of Pathology, Basic Medical Sciences Institute, Karachi, from January 2014 to January 2020 to evaluate the association of age with normal endometrial phases, hyperplasia, and endometrial carcinoma in the local population. The study was conducted on a total of 103 diagnosed cases. All participants underwent immunohistochemistry testing. The Endometrial malignancies were most common in women aged 61 to 70, with an average age of 54. Hyperplasia without atypia was most common in the age group of 31 to 40 years, with an average age of 33 years, while hyperplasia with atypia was common in women aged between 41 to 50 years. The secretory and proliferative phases were most common in the 4th and third decades of life, with an average age of 42 and 39, respectively. They concluded that endometrioid adenocarcinoma is the most prevalent endometrial malignancy with the highest risk during the 6th decade, while endometrial hyperplasia without atypia is the most prevalent type of hyperplasia with the highest risk during 4th decade of life.

Downloads

Download data is not yet available.

References

Deligdisch-Schor, L., and Miceli, A. M. (2020). "Hormonal Pathology of the Uterus," Springer.

Gokula Priya, M., Bargavi, E., and Julega, K. (2021). An overview of endometrial hyperplasia. J. Med. P'ceutical Allied. Sci 10.

Hamilton, C. A., Pothuri, B., Arend, R. C., Backes, F. J., Gehrig, P. A., Soliman, P. T., Thompson, J. S., Urban, R. R., and Burke, W. M. (2021). Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations. Gynecologic oncology 160, 817-826.

Karavasiloglou, N., Pestoni, G., Pannen, S. T., Schönenberger, K. A., Kuhn, T., and Rohrmann, S. (2022). How prevalent is a cancer-protective lifestyle? Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations in Switzerland. British journal of nutrition, 1-7.

Kenkhuis, M.-F., Mols, F., van Roekel, E. H., Breedveld-Peters, J. J., Breukink, S. O., Janssen-Heijnen, M. L., Keulen, E. T., van Duijnhoven, F. J., Weijenberg, M. P., and Bours, M. J. (2022). Longitudinal Associations of Adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) lifestyle recommendations with quality of life and symptoms in colorectal cancer survivors up to 24 months post-treatment. Cancers 14, 417.

Kim, S. R., Cloutier, B. T., Leung, S., Cochrane, D., Britton, H., Pina, A., Storness-Bliss, C., Farnell, D., Huang, L., and Shum, K. (2020). Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification. Gynecologic Oncology 158, 3-11.

Korn, A. R., Reedy, J., Brockton, N. T., Kahle, L. L., Mitrou, P., and Shams-White, M. M. (2022). The 2018 World Cancer Research Fund/American Institute for Cancer Research score and cancer risk: a longitudinal analysis in the NIH-AARP diet and health study. Cancer Epidemiology, Biomarkers & Prevention 31, 1983-1992.

Matsuo, K., Violette, C. J., Mandelbaum, R. S., Harris, C. A., Tavakoli, A., Klar, M., Shoupe, D., and Roman, L. D. (2022). Substantial variability in ovarian conservation at hysterectomy for endometrial hyperplasia. American Journal of Obstetrics and Gynecology 227, 255. e1-255. e18.

Poon, L. C., Shennan, A., Hyett, J. A., Kapur, A., Hadar, E., Divakar, H., McAuliffe, F., da Silva Costa, F., Von Dadelszen, P., and McIntyre, H. D. (2019). The International Federation of Gynecology and Obstetrics (FIGO) initiative on preeclampsia (PE): a pragmatic guide for first trimester screening and prevention. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 145, 1.

Rosen, M. W., Tasset, J., Kobernik, E. K., Smith, Y. R., Johnston, C., and Quint, E. H. (2019). Risk factors for endometrial cancer or hyperplasia in adolescents and women 25 years old or younger. Journal of pediatric and adolescent gynecology 32, 546-549.

Shams-White, M. M., Brockton, N. T., Mitrou, P., Romaguera, D., Brown, S., Bender, A., Kahle, L. L., and Reedy, J. (2019). Operationalizing the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations: a standardized scoring system. Nutrients 11, 1572.

Shi, L., Gu, Q., Zhang, F., Li, D., Ye, W., Zhong, Y., and Shi, X. (2021). Predictive factors of surgical site infection after hysterectomy for endometrial carcinoma: a retrospective analysis. BMC surgery 21, 1-7.

Tauseef, K., Zaffar, H., Usman, A., and Niaz, A. (2018). Morphological Spectrum of Endometrial Lesions. International Journal of Pathology, 145-148.

Wise, M. R., Jordan, V., Lagas, A., Showell, M., Wong, N., Lensen, S., and Farquhar, C. M. (2016). Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review. American journal of obstetrics and gynecology 214, 689. e1-689. e17.

Zhang, S., Gong, T.-T., Liu, F.-H., Jiang, Y.-T., Sun, H., Ma, X.-X., Zhao, Y.-H., and Wu, Q.-J. (2019). Global, regional, and national burden of endometrial cancer, 1990–2017: results from the global burden of disease study, 2017. Frontiers in oncology 9, 1440.